Prof. Günzburg Presented Klotho Delivery Method
The presentation highlighted an encapsulated-cell technique for potential protein treatment.
Updated on Sept. 24, 2026 in Biotech
Live Poll
Do you believe new cell-based therapies will successfully improve long-term treatment for patients?
Prof. Walter H. Günzburg presented an encapsulated-cell approach for alpha-Klotho delivery during the Second Annual Klotho Conference in Miami. The method utilizes specialized technology to provide a sustained protein source.
Why it matters
The approach seeks to determine if encapsulated cells can offer a more consistent supply of alpha-Klotho compared to traditional repeated protein dosing. This could improve the efficacy and longevity of potential future therapies.
The Austrianova Cell-in-a-Box technology encapsulates genetically modified cells to facilitate continuous protein secretion. The system is designed to shield these cells from the host immune system once implanted.
The players
Walter H. Günzburg
He is a professor who presented the research on encapsulated-cell alpha-Klotho delivery.
Klothonova
This is a 50/50 joint venture established between Avaí Bio and Austrianova to advance therapeutic research.
Austrianova
A biotech company that specializes in Cell-in-a-Box technology for medical applications.
Avaí Bio
This company is a partner in the Klothonova joint venture focusing on biotherapeutic innovation.
The details
Austrianova and Avaí Bio established the Klothonova joint venture to develop this preclinical program. The firms have already completed a GMP master cell bank to support ongoing process development efforts.
Timeline
The Klothonova joint venture was formed in 2025.
The Second Annual Klotho Conference occurred from September 18-19, 2026.
The outcome of the presentation was announced on September 24, 2026.
The Tech Race
This development represents the latest iteration of the Cell-in-a-Box encapsulation technology. It positions Klothonova within the competitive landscape of cell-based therapies that aim to replace traditional, short-lived protein injection treatments.
Patients and healthcare providers may eventually see a transition from frequent clinical dosing to more sustained, implantable treatment options. The current research remains in the preclinical phase, meaning no direct consumer impact exists at this time.
The takeaway
The study of encapsulated cells marks a significant shift in how researchers approach protein delivery. Future advancements in this area may offer a more durable therapeutic solution for patients requiring long-term protein regulation.
Further reading
For more information on innovations in the field, visit the Biotech section.
Source note: This article includes information reported by Firstwordpharma.
Live Poll
Do you believe new cell-based therapies will successfully improve long-term treatment for patients?
